共表达ER与HER2乳腺癌研究进展
Research Progress in Co-expression of ER and HER2 in Breast Cancer
摘要
随着肿瘤标志物的广泛应用,目前乳腺癌常根据肿瘤分子特征进行个体化治疗。表达雌激素受体(ER)的乳腺癌对内分泌治疗敏感,但表达人表皮生长因子受体2(HER2)的患者ER表达降低并增加患者对内分泌治疗的抵抗。全文探讨共表达ER和HER2乳腺癌的分子特征、交互应答途径及治疗策略。
出处
《肿瘤学杂志》
CAS
2009年第9期806-809,共4页
Journal of Chinese Oncology
参考文献1
-
1P. Kelly Marcom,Claudine Isaacs,Lyndsay Harris,Zee Wang Wong,Aruna Kommarreddy,Nellie Novielli,Gretchen Mann,Yu Tao,Matthew J. Ellis. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers[J] 2007,Breast Cancer Research and Treatment(1):43～49
